The drug-maker would cross the Rs 6,000-crore turnover milestone this year, with over 50 per cent being from exports. It has earmarked an ongoing investment of Rs 1,000 crore in existing facilities. The company was hopeful that biosimilar products from the company would be launched in early 2012. Cipla had recently invested in biotech companies in China and India and a plant was being set up in Goa to make biosimilar actives and formulations.
Drug major Cipla board has approved the acquisition of Mumbai based Meditab Specialities for a consideration of Rs 133.35 crore. Meditab has small and midsized formulation manufacturing facilities at multiple locations that make formulation products for Cipla. The acquisition would help Cipla expand its active pharmaceutical ingredients (API) and intermediaries international business through a manufacturing facility in China. It would facilitate entry into the high-growth Chinese domestic formulations market through the local manufacturing facility in China, besides supporting additional business opportunity in Africa through local manufacturing facilities in Uganda. It would also extend Cipla's existing relationship for research of stem-cell based products having facilities in India and Malaysia, through equity participation.
Cipla, is the one of the world’s major manufacturer of antiretroviral drugs (ARVs) to fight HIV/AIDS, as measured by units produced and distributed. The company makes drugs to treat cardiovascular disease, arthritis, diabetes, weight control, depression and many other health conditions, and its products are distributed in more than 180 countries worldwide.
crackcrack| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1660.95 |
| Dr. Reddys Lab | 1223.60 |
| Cipla | 1213.85 |
| Zydus Lifesciences | 923.70 |
| Lupin | 2320.00 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: